Fuad Mirzayev

3.0k total citations · 1 hit paper
25 papers, 704 citations indexed

About

Fuad Mirzayev is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Fuad Mirzayev has authored 25 papers receiving a total of 704 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 14 papers in Epidemiology and 7 papers in Surgery. Recurrent topics in Fuad Mirzayev's work include Tuberculosis Research and Epidemiology (22 papers), Pneumocystis jirovecii pneumonia detection and treatment (7 papers) and Pneumonia and Respiratory Infections (6 papers). Fuad Mirzayev is often cited by papers focused on Tuberculosis Research and Epidemiology (22 papers), Pneumocystis jirovecii pneumonia detection and treatment (7 papers) and Pneumonia and Respiratory Infections (6 papers). Fuad Mirzayev collaborates with scholars based in Switzerland, United States and Italy. Fuad Mirzayev's co-authors include Matteo Zignol, Linh Nguyen, Ernesto Jaramillo, Medea Gegia, Dennis Falzon, Katherine Floyd, Karin Weyer, Mario Raviǵlione, Licé González-Angulo and Kerri Viney and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Annals of Internal Medicine.

In The Last Decade

Fuad Mirzayev

24 papers receiving 678 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multidrug-resistant tuberculosis

2024 70 citations Keertan Dheda, Fuad Mirzayev et al. Nature Reviews Disease Primers profile →

Peers

Countries citing papers authored by Fuad Mirzayev

Since Specialization

Citations

This map shows the geographic impact of Fuad Mirzayev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fuad Mirzayev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fuad Mirzayev more than expected).

Fields of papers citing papers by Fuad Mirzayev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fuad Mirzayev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fuad Mirzayev. The network helps show where Fuad Mirzayev may publish in the future.

Co-authorship network of co-authors of Fuad Mirzayev

This figure shows the co-authorship network connecting the top 25 collaborators of Fuad Mirzayev. A scholar is included among the top collaborators of Fuad Mirzayev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fuad Mirzayev. Fuad Mirzayev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Drug-resistant tuberculosis: a priority pathogen for enhanced public health research and practice 2025 ·Clinical Microbiology Reviews ·H. Manisha Yapa, Emily MacLean, Nicolas A. Menzies, Peter J. Dodd, Anna Dean, Fuad Mirzayev, Samuel G. Schumacher, Linh Nguyen, Matteo Zignol, Greg J. Fox	0
2	GRADE Guidance: Using Thresholds for Judgments on Health Benefits and Harms in Decision Making (GRADE Guidance 42) 2025 ·Annals of Internal Medicine ·Wojtek Wiercioch, Gian Paolo Morgano, Thomas Piggott, Robby Nieuwlaat, Ignacio Neumann, Bernardo Sousa‐Pinto, Pablo Alonso‐Coello, Elie A. Akl, Lawrence Mbuagbaw, Fuad Mirzayev, Lorenzo Moja, Reem A. Mustafa, Daniele Piovani, Elena Parmelli, Zuleika Saz‐Parkinson, Samuel G. Schumacher, Ilse M. Verstijnen, Stefanos Bonovas, Holger J. Schünemann	2
3	Multidrug-resistant tuberculosis breakdown → 2024 ·Nature Reviews Disease Primers ·Keertan Dheda, Fuad Mirzayev, Daniela María Cirillo, Zarir Udwadia, Kelly E. Dooley, Kwok Chiu Chang, Shaheed Vally Omar, Anja Reuter, Tahlia Perumal, C. Robert Horsburgh, Megan Murray, Christoph Lange	70
4	Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis 2024 ·The Lancet Global Health ·Theresa Ryckman, Samuel G. Schumacher, Christian Lienhardt, Sedona Sweeney, David W. Dowdy, Fuad Mirzayev, Emily A. Kendall	6
5	The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis 2023 ·Clinical Infectious Diseases ·Tasnim Hasan, (unknown), Bern-Thomas Nyang’wa, Erica Egizi, Catherine Berry, Matthew Dodd, Salah Foraida, Medea Gegia, Mengchun Li, Fuad Mirzayev, (unknown), Ilaria Motta, Linh Nguyen, Samuel G. Schumacher, (unknown), Greg J. Fox	15
6	Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis 2023 ·Nature Communications ·Nicolas A. Menzies, Brian Allwood, Anna Dean, Peter J. Dodd, Rein M G J Houben, Lyndon P. James, Gwenan M. Knight, Jamilah Meghji, Linh Nguyen, Andrea Rachow, Samuel G. Schumacher, Fuad Mirzayev, Ted Cohen	19
7	Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and meta-analysis 2023 ·EClinicalMedicine ·Ioana D. Olaru, (unknown), Fuad Mirzayev, (unknown), Philip J. Kitchen, Samuel G. Schumacher, Claudia M. Denkinger	16
8	Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis 2023 ·Clinical Infectious Diseases ·(unknown), (unknown), (unknown), Ali Wagdy Mohamed, Fuad Mirzayev, Medea Gegia, Linh Nguyen, Samuel G. Schumacher, Payam Nahid, Radojka M. Savić	1
9	Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis 2022 ·SHILAP Revista de lepidopterología ·(unknown), Sandeep Juneja, (unknown), Mohamed A. Yassin, Grania Brigden, Eliud Wandwalo, (unknown), Fuad Mirzayev, Matteo Zignol	5
10	Situational analysis of 10 countries with a high burden of drug-resistant tuberculosis 2 years post-UNHLM declaration: progress and setbacks in a changing landscape 2021 ·International Journal of Infectious Diseases ·(unknown), Medea Gegia, D. F. Wares, Sarabjit Chadha, Fuad Mirzayev	18
11	Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date 2021 ·Drug Design Development and Therapy ·(unknown), Fuad Mirzayev, Susan M. Abdel‐Rahman	41
12	Using GRADE evidence to decision frameworks to choose from multiple interventions 2020 ·Journal of Clinical Epidemiology ·Thomas Piggott, Jan Brożek, Artur Nowak, (unknown), Bart Dietl, Zuleika Saz‐Parkinson, Fuad Mirzayev, Licé González-Angulo, Juan José Yepes-Núñez, Reem A. Mustafa, Grigorios I. Leontiadis, Romina Brignardello‐Petersen, Pablo Alonso‐Coello, Holger J. Schünemann	16
13	World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update 2020 ·European Respiratory Journal ·Fuad Mirzayev, Kerri Viney, Linh Nguyen, Licé González-Angulo, Medea Gegia, Ernesto Jaramillo, Matteo Zignol, Tereza Kasaeva	155
14	Ethical issues in tuberculosis screening and the use of new drugs for prisoners 2020 ·The International Journal of Tuberculosis and Lung Disease ·Bernice S. Elger, Fuad Mirzayev, (unknown), (unknown)	3
15	Tuberculosis Supranational Reference Laboratories 2019 ·Clinics in Chest Medicine ·Christopher Gilpin, Fuad Mirzayev	2
16	Mitigation of Discordant Rifampicin-Susceptibility Results Obtained by Xpert Mycobacterium tuberculosis/ Rifampicin and Mycobacterium Growth Indicator Tube 2017 ·Microbial Drug Resistance ·(unknown), Rafail Mehdiyev, Kai Blöndal, (unknown), Fuad Mirzayev, Doris Hillemann, (unknown), Alan Altraja	8
17	Interpretation of indeterminate RIF-susceptibility results obtained by rapid molecular diagnostics test 2016 ·(unknown), Rafail Mehdiyev, Kai Blöndal, (unknown), Fuad Mirzayev, Doris Hillemann, (unknown), Alan Altraja	2
18	Multidrug-resistant tuberculosis around the world: what progress has been made? 2014 ·European Respiratory Journal ·Dennis Falzon, Fuad Mirzayev, Fraser Wares, Inés García Baena, Matteo Zignol, Linh Nguyen, Karin Weyer, Ernesto Jaramillo, Katherine Floyd, Mario Raviǵlione	102
19	Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF 2012 ·European Respiratory Journal ·Karin Weyer, Fuad Mirzayev, Giovanni Battista Migliori, Wayne Van Gemert, Lia D’Ambrosio, Matteo Zignol, Katherine Floyd, Rosella Centis, Daniela María Cirillo, Enrico Tortoli, Chris Gilpin, (unknown), Dennis Falzon, Mario Raviǵlione	167
20	Drug-Resistant Tuberculosis, KwaZulu-Natal, South Africa, 2001–2007 2011 ·Emerging infectious diseases ·Kristina Wallengren, Fabio Scano, Paul Nunn, Bruce Margot, (unknown), Brian Williams, Alexander S. Pym, (unknown), Fuad Mirzayev, (unknown), Lindiwe Mvusi, Yogan Pillay	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact